Sunday, April 7, 2013

India’s Novartis Decision; New York Times, 4/4/13

Editorial Board, New York Times; India’s Novartis Decision: "The ruling will allow the sale of generic versions of Gleevec in India and other countries where it is not patented at less than one-20th of the roughly $70,000 a year it costs in the United States. It will not affect the price of the drug in America. This case is unique because it concerns an innovative and useful drug whose creation happened to straddle the change in Indian patent law. The ruling is important, nonetheless, because it establishes a limited precedent that requires drug companies to show real improvements in efficacy before they can get patent protection on updates to existing drugs in India. That could help poor patients get drugs at prices they can afford while preserving an incentive for true innovation."

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.